FENC

Fennec Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing products for cancer supportive care. The company's lead product, PEDMARK (sodium thiosulfate), is approved to reduce the risk of ototoxicity associated with cisplatin chemotherapy in pediatric patients. Ototoxicity, or hearing loss, is a serious side effect of platinum-based chemotherapy that can permanently affect children's development and quality of life. PEDMARK represents the first FDA-approved treatment specifically designed to prevent this complication. Headquartered in Research Triangle Park, North Carolina, Fennec is working to expand PEDMARK's use and explore additional applications of its technology platform to improve outcomes for pediatric cancer patients undergoing chemotherapy.